Pulmonology (Lung)

Divya Verma; Saadia A. Faiz; Vickie R. Shannon; Ajay Sheshadri; Mehmet Altan

doi:10.1007/978-3-031-00241-0_14

Pulmonology (Lung)

Divya Verma, Saadia A. Faiz, Vickie R. Shannon, Ajay Sheshadri, Mehmet Altan

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

The use of immune checkpoint inhibitors (ICIs), which include drugs that target programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), has rapidly expanded over the past decade due to an ever-growing number of indications to treat different cancers. As their use has increased, so has recognition of immune-related side effects. The pulmonary toxicities of ICIs are less common than other immune-mediated toxicities but carry significant morbidity and are the most common cause of treatment-related mortality. This chapter will discuss the various pulmonary toxicities induced by ICIs but will focus most heavily on ICI pneumonitis.

Original language	English (US)
Title of host publication	Managing Immunotherapy Related Organ Toxicities
Subtitle of host publication	A Practical Guide
Publisher	Springer International Publishing
Pages	275-299
Number of pages	25
ISBN (Electronic)	9783031002410
ISBN (Print)	9783031002403
DOIs	https://doi.org/10.1007/978-3-031-00241-0_14
State	Published - Jan 1 2022

Keywords

Lung injury
Organizing pneumonia
Pneumonitis
Sarcoidosis

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1007/978-3-031-00241-0_14

Cite this

@inbook{bb2b827abfa24f21ab738e9e7d83d889,

title = "Pulmonology (Lung)",

abstract = "The use of immune checkpoint inhibitors (ICIs), which include drugs that target programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), has rapidly expanded over the past decade due to an ever-growing number of indications to treat different cancers. As their use has increased, so has recognition of immune-related side effects. The pulmonary toxicities of ICIs are less common than other immune-mediated toxicities but carry significant morbidity and are the most common cause of treatment-related mortality. This chapter will discuss the various pulmonary toxicities induced by ICIs but will focus most heavily on ICI pneumonitis.",

keywords = "Lung injury, Organizing pneumonia, Pneumonitis, Sarcoidosis",

author = "Divya Verma and Faiz, {Saadia A.} and Shannon, {Vickie R.} and Ajay Sheshadri and Mehmet Altan",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-00241-0_14",

language = "English (US)",

isbn = "9783031002403",

pages = "275--299",

booktitle = "Managing Immunotherapy Related Organ Toxicities",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Pulmonology (Lung)

AU - Verma, Divya

AU - Faiz, Saadia A.

AU - Shannon, Vickie R.

AU - Sheshadri, Ajay

AU - Altan, Mehmet

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The use of immune checkpoint inhibitors (ICIs), which include drugs that target programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), has rapidly expanded over the past decade due to an ever-growing number of indications to treat different cancers. As their use has increased, so has recognition of immune-related side effects. The pulmonary toxicities of ICIs are less common than other immune-mediated toxicities but carry significant morbidity and are the most common cause of treatment-related mortality. This chapter will discuss the various pulmonary toxicities induced by ICIs but will focus most heavily on ICI pneumonitis.

AB - The use of immune checkpoint inhibitors (ICIs), which include drugs that target programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), has rapidly expanded over the past decade due to an ever-growing number of indications to treat different cancers. As their use has increased, so has recognition of immune-related side effects. The pulmonary toxicities of ICIs are less common than other immune-mediated toxicities but carry significant morbidity and are the most common cause of treatment-related mortality. This chapter will discuss the various pulmonary toxicities induced by ICIs but will focus most heavily on ICI pneumonitis.

KW - Lung injury

KW - Organizing pneumonia

KW - Pneumonitis

KW - Sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85161982448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161982448&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-00241-0_14

DO - 10.1007/978-3-031-00241-0_14

M3 - Chapter

AN - SCOPUS:85161982448

SN - 9783031002403

SP - 275

EP - 299

BT - Managing Immunotherapy Related Organ Toxicities

PB - Springer International Publishing

ER -

Pulmonology (Lung)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this